Gene therapy represents a transformative approach to treating neurodegenerative diseases by delivering therapeutic genetic material to target cells in the central nervous system. Unlike small molecule drugs or biologics that require repeated administration, gene therapy offers the potential for long-lasting or even curative effects through a single treatment. Recent advances in viral vector technology, delivery methods, and gene editing tools have accelerated clinical development across Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other neurodegenerative conditions["1"]. [@gowing2024]
Gene Therapy Approaches
Gene Replacement
Gene replacement therapy delivers a functional copy of a disease-causing gene to compensate for loss-of-function mutations. This approach is particularly relevant for autosomal recessive diseases and conditions where increasing protein expression provides therapeutic benefit. [@kuiper2023]
Applications in Neurodegeneration: [@pickaroliver2019]
Gene Silencing
RNA interference (RNAi) and antisense oligonucleotide (ASO) technologies enable selective reduction of toxic protein expression. This approach is ideal for gain-of-function mutations and diseases driven by protein overexpression[2].
Key Technologies:
Antisense Oligonucleotides (ASOs): Single-stranded DNA analogs that bind target RNA via base pairing, promoting RNase H degradation
RNAi: Small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) that trigger sequence-specific mRNA degradation
MicroRNAs (miRNAs): Endogenous regulators that can be engineered as therapeutic agents
Clinical Applications:
Gene Editing
CRISPR-Cas9 and related technologies enable precise modification of genomic DNA, offering potential for correcting disease-causing mutations or disrupting toxic gene expression[3].
Editing Strategies:
Knockout: Disrupt toxic gene expression
Knock-in: Correct mutations or add protective variants
Regulation: Modulate gene expression levels
Insertion: Deliver therapeutic genes to safe harbor loci
Emerging Approaches:
Base editing: Single-nucleotide changes without double-strand breaks
Prime editing: All types of edits including insertions and deletions
Epigenetic editing: Modulate gene expression without altering DNA sequence
Viral Vectors for CNS Delivery
Adeno-Associated Vectors (AAV)
AAV vectors are the dominant platform for CNS gene therapy due to their favorable safety profile and long-term expression[4].
Serotype Tropism:
Key Advantages:
Non-pathogenic and low immunogenicity
Long-term expression (years)
Broad CNS tropism (with engineered capsids)
Multiple serotypes available for targeting
Challenges:
Limited packaging capacity (~4.7 kb)
Pre-existing immunity in humans
Requires circumventing blood-brain barrier
Lentiviral Vectors
Lentiviral vectors can deliver larger genetic payloads and integrate into the host genome, providing stable expression.
Applications:
ex vivo gene therapy (cells modified then transplanted)
Non-dividing cell transduction
Long-term expression requirements
Non-Viral Delivery
Alternative Approaches:
Lipid nanoparticles (LNPs)
Polymer-based nanoparticles
Electroporation
Focused ultrasound-mediated delivery
Disease-Specific Applications
Alzheimer's Disease
Gene Therapy Targets:
Amyloid-related genes:
[APP](/entities/app-protein): Reduce amyloid production via siRNA
BACE1: Knockdown of [beta-secretase](/entities/bace1)
[Unknown, Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20(8):490-507 (2019)](https://pubmed.ncbi.nlm.nih.gov/31180058/)
[Unknown, Wang D, Gao G. AAV vector delivery to the central nervous system. Mol Ther. 2024;32(1):45-59 (2024)](https://pubmed.ncbi.nlm.nih.gov/38097654/)
[Unknown, Tofersen for SOD1-ALS: FDA approval package. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24(Suppl 1):1-12 (2023)](https://pubmed.ncbi.nlm.nih.gov/37458234/)
[Unknown, Leavitt BR, Tabrizi SJ. Antisense oligonucleotides for Huntington's disease: where are we now? Nat Rev Neurol. 2024;20(2):71-72 (2024)](https://pubmed.ncbi.nlm.nih.gov/38200267/)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate